【佳学基因检测】神经精神疾病的新治疗靶点：神经表观基因组

精神病基因检测龙头企业国产

在精神疾病的靶向药物治疗高峰论坛中，博士医师年度双基练习体会到《Curr Pharm Des》在. 2014;20(11):1831-9.发表了一篇题目为《神经精神疾病的新治疗靶点：神经表观基因组》神经精神系统疾病的先进治疗方案探讨的靶向药物治疗基因检测临床研究文章。该研究由Lucio Tremolizzo, Virginia Rodriguez-Menendez, Elisa Conti, Chiara Paola Zoia, Guido Cavaletti, Carlo Ferrarese等完成。促进了神表观基因组在治疗性基因检测的研究和创新，进一步强调了基因信息检测与分析的重要性。

神经疾病遗传阻断及精准治疗临床研究内容关键词：

整合基因组学,多组学,网络建模,精神疾病,系统生物学

精神类疾病用药指导基因检测临床应用结果

由于专用药物的广泛可用性，神经表观基因组，即神经系统的表观基因组，在过去几年中已成为治疗学的关注点。在生理学和病理学中，神经表观遗传学的关键作用肯定是通过神经系统中不断发生的高度动态的结构和功能重排，全球称为可塑性。此外，由于越来越多的实验数据和这些疾病的大多数散发形式下基因与环境之间协同相互作用的证据，几种神经精神疾病的病理生理学可能涉及表观遗传机制的想法越来越多。在本文中，神经及精神疾病基于基因检测的精准药物研究开发团队介绿了在神经精神病学领域使用表观基因组修饰药物的现有证据，简要描述每种疾病的表观遗传失调的基本假设。

神经及精神疾病及其并发征、合并征国际数据库描述：

The neuroepigenome, i.e., the epigenome of the nervous system, has become interesting for therapeutics in the last years due to widespread availability of dedicated drugs. A pivotal role for neuroepigenetics is certainly implied, both in physiology and pathology, by the highly dynamic structural and functional rearrangements that constantly occur into the nervous system, globally known as plasticity. Moreover, the idea that the pathophysiology of several neuropsychiatric disorders might involve epigenetic mechanisms is increasingly taking place due to accumulating experimental data and by the evidence of a synergistic interaction between genes and environment beneath most sporadic forms of these diseases. In this paper we will review the available evidence on the use of epigenome-modifying drugs in the field of neuropsychiatry, shortly describing for each disease the underlying assumptions of an epigenetic dysregulation.